Latest Pharma and Biotech News
Biotechnology
15 April 2026 USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction.
Today's issue
Refine search
Biotechnology
Enodia Therapeutics, a privately-held French biotech developing small molecule therapies targeting a unique form of protein degradation at the point of synthesis, has appointed Yvonne McGrath as chief scientific officer (CSO). 15 April 2026
Biotechnology
US clinical-stage biotechnology company Beeline Medicines today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. 15 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today announced that Health Canada has approved Neffy 2mg adrenaline (epinephrine) nasal spray for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis in adult and paediatric patients (≥30 kg). 15 April 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has determined that only a clinical trial - rather than a nonclinical or observational study - will be sufficient to prove the safety of Eli Lilly’s new obesity drug, Foundayo (orforglipron). 15 April 2026
Pharmaceutical
India’s Rubicon Research today announced the acquisition of an 85% equity ownership in Arinna Lifesciences from its current shareholders. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
French immunotherapy company OSE Immunotherapeutics provided a senior management update. 15 April 2026
Biotechnology
German drug discovery company Evotec today announced the appointment of Dr Ingrid Müller as chief operating officer (COO). 15 April 2026
Biotechnology
San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. 15 April 2026
Pharmaceutical
US anti-virals specialist Gilead Sciences announced that the US State Department, the US President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead’s twice-yearly injectable HIV prevention medicine, lenacapavir (marketed under the tradename Yeztugo), to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. 15 April 2026
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Biotechnology
The US Food and Drug Administration (FDA) today issued a draft guidance for sponsors seeking approval of human gene therapy products involving genome editing technologies. 14 April 2026
Pharmaceutical
The local unit of US biotech major Biogen today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization to the high dose regimen (50/28mg) of Spinraza (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA). 14 April 2026
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-322 trial. 14 April 2026
Pharmaceutical
US biopharma Travere Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Filspari (sparsentan) to reduce proteinuria in adult and pediatric patients aged eight years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. 14 April 2026
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Biotechnology
Anglo-Irish biopharma SynOx Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to emactuzumab for the treatment of tenosynovial giant cell tumors (TGCT) patients that are not amenable to or who would not benefit from surgery. 14 April 2026
Pharmaceutical
Novo Nordisk has announced a strategic partnership with OpenAI, the US AI research and deployment company. 14 April 2026
Generics
India’s generics industry appears to be reshaping the weight loss and diabetes drug market, with Eli Lilly’s share in the GLP-1 category slipping sharply in March. 14 April 2026
All news
Biotechnology
Enodia Therapeutics, a privately-held French biotech developing small molecule therapies targeting a unique form of protein degradation at the point of synthesis, has appointed Yvonne McGrath as chief scientific officer (CSO). 15 April 2026
Biotechnology
US clinical-stage biotechnology company Beeline Medicines today announced its official debut with the mission of developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases. 15 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today announced that Health Canada has approved Neffy 2mg adrenaline (epinephrine) nasal spray for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis in adult and paediatric patients (≥30 kg). 15 April 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has determined that only a clinical trial - rather than a nonclinical or observational study - will be sufficient to prove the safety of Eli Lilly’s new obesity drug, Foundayo (orforglipron). 15 April 2026
Pharmaceutical
India’s Rubicon Research today announced the acquisition of an 85% equity ownership in Arinna Lifesciences from its current shareholders. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
French immunotherapy company OSE Immunotherapeutics provided a senior management update. 15 April 2026
Biotechnology
German drug discovery company Evotec today announced the appointment of Dr Ingrid Müller as chief operating officer (COO). 15 April 2026
Biotechnology
San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. 15 April 2026
Pharmaceutical
US anti-virals specialist Gilead Sciences announced that the US State Department, the US President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead’s twice-yearly injectable HIV prevention medicine, lenacapavir (marketed under the tradename Yeztugo), to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. 15 April 2026
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Biotechnology
The US Food and Drug Administration (FDA) today issued a draft guidance for sponsors seeking approval of human gene therapy products involving genome editing technologies. 14 April 2026
Pharmaceutical
The local unit of US biotech major Biogen today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization to the high dose regimen (50/28mg) of Spinraza (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA). 14 April 2026
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-322 trial. 14 April 2026
Pharmaceutical
US biopharma Travere Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Filspari (sparsentan) to reduce proteinuria in adult and pediatric patients aged eight years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. 14 April 2026
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Biotechnology
Anglo-Irish biopharma SynOx Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to emactuzumab for the treatment of tenosynovial giant cell tumors (TGCT) patients that are not amenable to or who would not benefit from surgery. 14 April 2026
Pharmaceutical
Novo Nordisk has announced a strategic partnership with OpenAI, the US AI research and deployment company. 14 April 2026
Generics
India’s generics industry appears to be reshaping the weight loss and diabetes drug market, with Eli Lilly’s share in the GLP-1 category slipping sharply in March. 14 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze